Ranbaxy Labs Q4CY11 PAT seen at Rs 575cr

Ranbaxy Laboratories is to announce its Q4CY11. According to CNBC-TV18 estimates, the company's Q4CY11 revenues are seen up 48% to Rs 3156 crore versus Rs 2129 crore.

Its EBITDA at Rs 832 crore versus Rs 230 crore. Its OPM 26.4% versus 10.8%. The company's PAT is seen at Rs 575 crore versus loss of Rs 97.5 crore. Watch for: Revenue growth due to exclusivity from Lipitor generic and authorized generic launch of Caduet Analysts factoring in USD 200 million or Rs 980 crore from Lipitor generic